We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aurinia (AUPH) Surges 6.6%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Aurinia Pharmaceuticals (AUPH - Free Report) shares rallied 6.6% in the last trading session to close at $29.84. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 20.5% gain over the past four weeks.
Shares of Aurinia Pharmaceuticals have been consistently surging, following reports of its proposed acquisition by pharma giant Bristol Myers Squibb. Earlier this year, Aurinia received FDA approval for the first drug in the company’s commercial portfolio, Lupkynis, to treat active lupus nephritis (LN), a disease that causes irreversible kidney damage. While the news is yet to be confirmed by either of the companies, investors remain optimistic about the deal as a potential acquisition of Aurinia will add a recently approved LN drug to Bristol Myers’ commercial portfolio.
This biotechnology company is expected to post quarterly loss of $0.31 per share in its upcoming report, which represents a year-over-year change of -10.7%. Revenues are expected to be $14.7 million, up 48906.7% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Aurinia, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on AUPH going forward to see if this recent jump can turn into more strength down the road.
Image: Bigstock
Aurinia (AUPH) Surges 6.6%: Is This an Indication of Further Gains?
Aurinia Pharmaceuticals (AUPH - Free Report) shares rallied 6.6% in the last trading session to close at $29.84. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 20.5% gain over the past four weeks.
Shares of Aurinia Pharmaceuticals have been consistently surging, following reports of its proposed acquisition by pharma giant Bristol Myers Squibb. Earlier this year, Aurinia received FDA approval for the first drug in the company’s commercial portfolio, Lupkynis, to treat active lupus nephritis (LN), a disease that causes irreversible kidney damage. While the news is yet to be confirmed by either of the companies, investors remain optimistic about the deal as a potential acquisition of Aurinia will add a recently approved LN drug to Bristol Myers’ commercial portfolio.
This biotechnology company is expected to post quarterly loss of $0.31 per share in its upcoming report, which represents a year-over-year change of -10.7%. Revenues are expected to be $14.7 million, up 48906.7% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Aurinia, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on AUPH going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>